Delayed treatment with ceftriaxone increases glutamate transporter mRNA in cortex and hippocampus. by Simone A. A. Romariz (16541996)

Subjects:

S1 Data - by Elelbin A. Ortiz (8655285)

Subjects:

Discovery of the Triazolo[1,5‑<i>a</i>]Pyrimidine-Based Derivative WS-898 as a Highly Efficacious and Orally Bioavailable ABCB1 Inhibitor Capable of Overcoming Multidrug Resistance... by Shuai Wang (109515)

Subjects:

Binding of neuraminidase inhibitory antibodies to cells expressing 245 NA Gly+/- proteins. by Harrison Powell (9040128)

Subjects:

Effect of neuraminidase inhibitory antibodies on virus growth. by Harrison Powell (9040128)

Subjects:

S1 Data - by Simone A. A. Romariz (16541996)

Subjects:

Modified Racine score for PTZ-induced seizures. From [28]. by Simone A. A. Romariz (16541996)

Subjects:

CRISPR-Cas9 generated <i>syt7a</i> mutant alleles complement the <i>escapist p404</i> mutation. by Elelbin A. Ortiz (8655285)

Subjects:

Time-dependent effects of CCI on glutamate transporter mRNA. by Simone A. A. Romariz (16541996)

Subjects:

Discovery of the Triazolo[1,5‑<i>a</i>]Pyrimidine-Based Derivative WS-898 as a Highly Efficacious and Orally Bioavailable ABCB1 Inhibitor Capable of Overcoming Multidrug Resistance... by Shuai Wang (109515)

Subjects:

Chronic, but not acute, CCI mice have increased susceptibility to 30mg/kg PTZ. by Simone A. A. Romariz (16541996)

Subjects:

Delayed treatment with ceftriaxone reduced seizure susceptibility in CCI mice. by Simone A. A. Romariz (16541996)

Subjects:

RNA sequencing linkage analysis identifies a single base pair change on Chromosome 25 that is tightly linked to the <i>escapist</i> hypersensitive phenotype. by Elelbin A. Ortiz (8655285)

Subjects:

CRISPR guide sequences. by Elelbin A. Ortiz (8655285)

Subjects:

The abundance of core fucosylation and bisecting modification in N-glycan and glycoprotein levels. by Jie Chen (5892)

“…<p>The abundance of core fucosylation and bisecting modification in N-glycan and glycoprotein levels were illustrated using DSA-FACE and serum lectin blot. (A) and (B): The abundance of total core fucosylation residues (the sum of Peak1, 2, 3, 4, 6, 7 and Peak10) from DSA-FACE decreased in LCMM patients (n = 42) than that in healthy controls (n = 42), and decreased according to the severity of the disease [moderate LCMM (n = 14) and severe LCMM (n = 28)]. …”

Peak abundances for the N-glycans which had the obvious overall changes among control subjects, moderate and severe LCMM subjects. by Jie Chen (5892)

Hypothetical illustration of the two types of variability addressed in this paper. by Rebecca A. Lundwall (333179)

Image_3_Non-Linear Correlation Between Tumor Size and Survival Outcomes for Parathyroid Carcinoma: A SEER Population-Based Cohort Study.tif by Kun Zhang (108291)

“…Multivariate Cox analysis revealed age, no surgery, and debulking surgery as consistent predictors of lower OS and CSS.</p>Conclusions<p>A non-linear correlation between tumor size and death risk has been identified in patients with PC, along with an accurate size threshold at which survival rates sharply decrease. …”

Image_1_Non-Linear Correlation Between Tumor Size and Survival Outcomes for Parathyroid Carcinoma: A SEER Population-Based Cohort Study.tif by Kun Zhang (108291)

“…Multivariate Cox analysis revealed age, no surgery, and debulking surgery as consistent predictors of lower OS and CSS.</p>Conclusions<p>A non-linear correlation between tumor size and death risk has been identified in patients with PC, along with an accurate size threshold at which survival rates sharply decrease. …”

Image_2_Non-Linear Correlation Between Tumor Size and Survival Outcomes for Parathyroid Carcinoma: A SEER Population-Based Cohort Study.tif by Kun Zhang (108291)

“…Multivariate Cox analysis revealed age, no surgery, and debulking surgery as consistent predictors of lower OS and CSS.</p>Conclusions<p>A non-linear correlation between tumor size and death risk has been identified in patients with PC, along with an accurate size threshold at which survival rates sharply decrease. …”